Background
Methods
Data source and management
Outcomes
Analysis strategy
Results
Participation flow
Overall SPC risk, univariate estimates
O | E | PYR | SIR | (95% CI) | EARb
| (95% CI) | ||
---|---|---|---|---|---|---|---|---|
All patients
| 21,226 | 15,555.59 | 1,440,960 | 1.36 | (1.35-1.38) | 39.4 | (37.4-41.3) | |
Gender
| Male | 14,555 | 10,514.87 | 689,115 | 1.38 | (1.36-1.41) | 58.6 | (55.2-62.1) |
Female | 6,671 | 5,040.73 | 751,845 | 1.32 | (1.29-1.36) | 21.7 | (19.6-23.8) | |
Age at first cancer diagnosis
| ≤ 44 y | 909 | 424.88 | 210,515 | 2.14 | (2.00-2.28) | 23.0 | (20.2-25.9) |
45 y-54 y | 2,592 | 1,270.67 | 236,678 | 2.04 | (1.96-2.12) | 55.8 | (51.7-60.1) | |
55 y-64 y | 5,284 | 3,500.56 | 334,536 | 1.51 | (1.47-1.55) | 53.3 | (49.1-57.6) | |
65 y-74 y | 7,772 | 6,235.67 | 406,356 | 1.25 | (1.22-1.27) | 37.8 | (33.6-42.1) | |
≥ 75 | 4,669 | 4,123.81 | 252,874 | 1.13 | (1.10-1.17) | 21.6 | (16.3-26.9) | |
Year of first cancer diagnosis
| 1989-1994 | 7,512 | 5,406.49 | 517,048 | 1.39 | (1.36-1.42) | 40.7 | (37.5-44.0) |
1995-1999 | 7,679 | 5,634.00 | 520,856 | 1.36 | (1.33-1.39) | 39.3 | (36.0-42.6) | |
2000-2004 | 6,035 | 4,515.10 | 403,057 | 1.34 | (1.30-1.37) | 37.7 | (34.0-41.5) | |
Follow-up
| ≥ 2 m- < 1 y | 3,170 | 2,280.81 | 213,502 | 1.39 | (1.34-1.44) | 41.6 | (36.5-46.9) |
≥ 1 y- < 2 y | 3,034 | 2,229.98 | 210,970 | 1.36 | (1.31-1.41) | 38.1 | (33.0-43.3) | |
≥ 2 y- < 4 y | 4,983 | 3,665.14 | 343,730 | 1.36 | (1.32-1.40) | 38.3 | (34.3-42.4) | |
≥ 4 y- < 6 y | 3,504 | 2,614.81 | 241,999 | 1.34 | (1.30-1.39) | 36.7 | (32.0-41.6) | |
≥ 6 y- < 8 y | 2,522 | 1,815.96 | 166,357 | 1.39 | (1.34-1.44) | 42.4 | (36.6-48.5) | |
≥ 8 y- < 10 y | 1,664 | 1,239.15 | 112,267 | 1.34 | (1.28-1.41) | 37.8 | (30.8-45.1) | |
≥ 10 y | 2,349 | 1,709.75 | 152,135 | 1.37 | (1.32-1.43) | 42.0 | (35.8-48.4) |
Males | Females | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
(N = 160, 807) | (N = 129,160) | |||||||||||
First cancer site | O | E | PYR | SIR | EARb
| (95% CI) | O | E | PYR | SIR | EARb
| (95% CI) |
Lip | 111 | 80.66 | 4,081 | 1.38* | 74.3* | (26.1-129.9) | 13 | 8.44 | 806 | 1.54 | 56.6 | (-18.9-171.2) |
Tongue and lingual tonsil | 329 | 90.84 | 6,794 | 3.62* | 350.5* | (299.6-405.8) | 41 | 15.99 | 1,886 | 2.56* | 132.6* | (71.2-210.2) |
Oral cavity | 536 | 129.77 | 10,034 | 4.13* | 404.9* | (360.6-452.0) | 83 | 23.36 | 2,863 | 3.55* | 208.3* | (149.3-277.8) |
Salivary glands | 29 | 20.45 | 1,480 | 1.42 | 57.8 | (-7.0-143.3) | 14 | 12.38 | 1,569 | 1.13 | 10.3 | (-30.1-70.8) |
Oropharynx | 550 | 129.86 | 10,157 | 4.24* | 413.7* | (369.3-460.9) | 52 | 14.54 | 1,813 | 3.58* | 206.6* | (134.0-295.9) |
Nasopharynx | 13 | 12.90 | 1,223 | 1.01 | 0.8 | (-49.0-76.2) | 8 | 3.33 | 535 | 2.41* | 87.4* | (2.2-232.6) |
Hypopharynx | 496 | 129.23 | 9,334 | 3.84* | 392.9* | (347.2-441.8) | 27 | 4.40 | 577 | 6.13* | 391.8* | (232.1-604.9) |
Head and neckc
| 1,981 | 509.07 | 38,731 | 3.89* | 380.0* | (357.8-403.1) | 214 | 62.40 | 7,781 | 3.43* | 194.8* | (159.2-234.3) |
Oesophagus | 290 | 119.03 | 7,367 | 2.44* | 232.1* | (188.1-280.1) | 27 | 11.27 | 1,244 | 2.40* | 126.5* | (52.4-225.2) |
Stomach | 240 | 233.16 | 12,773 | 1.03 | 5.4 | (-17.7-30.7) | 87 | 83.55 | 8,739 | 1.04 | 3.9 | (-15.9-27.2) |
Small intestine | 32 | 31.37 | 1,848 | 1.02 | 3.4 | (-51.4-74.7) | 15 | 15.39 | 1,716 | 0.97 | -2.3 | (-40.8-54.5) |
Colorectum | 1,996 | 1,843.60 | 97,268 | 1.08* | 15.7* | (6.8-24.9) | 935 | 792.53 | 87,123 | 1.18* | 16.4* | (9.6-23.5) |
Colon | 1,185 | 1,060.19 | 55,504 | 1.12* | 22.5* | (10.5-35.0) | 590 | 491.42 | 54,649 | 1.20* | 18.0* | (9.5-27.1) |
Rectum | 810 | 783.28 | 41,747 | 1.03 | 6.4 | (-6.7-20.2) | 344 | 300.88 | 32,443 | 1.14* | 13.3* | (2.4-25.1) |
Liver, primary | 135 | 120.50 | 6,749 | 1.12 | 21.5 | (-10.8-58.2) | 23 | 13.82 | 1,709 | 1.66* | 53.7* | (4.4-121.1) |
Gallbladder and biliary tract | 30 | 38.16 | 1,950 | 0.79 | -41.9 | (-91.9-23.9) | 31 | 24.89 | 2,463 | 1.25 | 24.8 | (-15.5-77.6) |
Pancreas | 33 | 49.39 | 2,948 | 0.67* | -55.6* | (-90.5--10.3) | 25 | 23.53 | 2,730 | 1.06 | 5.4 | (-27.0-49.0) |
Nasal cavities and sinuses | 50 | 42.29 | 2,430 | 1.18 | 31.7 | (-21.3-97.2) | 3 | 5.90 | 650 | 0.51 | -44.5 | (-81.4-44.1) |
Larynx | 853 | 323.02 | 19,900 | 2.64* | 266.3* | (238.0-296.1) | 58 | 16.93 | 1,995 | 3.43* | 205.9* | (135.9-291.0) |
Lung, bronchus and trachea | 855 | 599.96 | 41,161 | 1.43* | 62.0* | (48.3-76.4) | 96 | 72.95 | 9,446 | 1.32* | 24.4* | (5.1-46.9) |
Pleura | 8 | 13.92 | 776 | 0.57 | -76.2 | (-134.9-23.8) | 3 | 2.45 | 284 | 1.22 | 19.3 | (-65.1-222.3) |
Bone and cartilages | 16 | 11.53 | 2,306 | 1.39 | 19.4 | (-10.4-62.7) | 11 | 8.25 | 2,087 | 1.33 | 13.2 | (-13.2-54.8) |
Soft tissue | 67 | 55.74 | 4,965 | 1.20 | 22.7 | (-7.7-59.1) | 39 | 24.00 | 3,951 | 1.62* | 38.0* | (9.4-74.2) |
Melanoma of skin | 303 | 258.43 | 20,881 | 1.17* | 21.3* | (5.5-38.6) | 288 | 208.83 | 32,126 | 1.38* | 24.6* | (14.6-35.6) |
Breast | 52 | 45.45 | 2,282 | 1.14 | 28.7 | (-29.0-99.6) | 2,476 | 1,885.48 | 351,434 | 1.31* | 16.8* | (14.1-19.6) |
Cervix uteri | - | - | - | - | - | - | 265 | 173.92 | 28,122 | 1.52* | 32.4* | (21.4-44.4) |
Corpus uteri | - | - | - | - | - | - | 511 | 370.65 | 41,147 | 1.38* | 34.1* | (23.6-45.4) |
Ovary and uterine adnexa | - | - | - | - | - | - | 189 | 168.03 | 22,829 | 1.12 | 9.2 | (-2.2-21.9) |
Vagina and vulva | - | - | - | - | - | - | 59 | 39.51 | 4,219 | 1.49* | 46.2* | (12.8-86.7) |
Prostate | 3,880 | 3,500.52 | 230,582 | 1.11* | 16.5* | (11.2-21.8) | - | - | - | - | - | - |
Testis | 86 | 59.42 | 19,448 | 1.45* | 13.7* | (4.8-24.1) | - | - | - | - | - | - |
Penis | 43 | 42.20 | 2,303 | 1.02 | 3.5 | (-48.1-68.3) | - | - | - | - | - | - |
Bladder | 1,192 | 729.56 | 38,002 | 1.63* | 121.7* | (104.1-140.0) | 99 | 79.73 | 7,772 | 1.24* | 24.8* | (0.9-52.5) |
Kidney | 660 | 471.41 | 28,385 | 1.40* | 66.4* | (49.0-84.9) | 198 | 149.07 | 17,327 | 1.33* | 28.2* | (12.9-45.3) |
Melanoma of choroid | 23 | 19.49 | 1,361 | 1.18 | 25.8 | (-36.1-110.4) | 14 | 12.84 | 1,465 | 1.09 | 7.9 | (-35.4-72.7) |
Brain | 24 | 30.03 | 5,546 | 0.80 | -10.9 | (-26.4-10.2) | 20 | 16.84 | 4,506 | 1.19 | 7.0 | (-10.3-31.2) |
Thyroid gland | 88 | 62.22 | 7,369 | 1.41* | 35.0* | (11.3-62.7) | 244 | 174.12 | 31,397 | 1.40* | 22.3* | (12.8-32.6) |
Hodgkin’s disease | 69 | 40.59 | 8,338 | 1.70* | 34.1* | (15.7-56.0) | 38 | 22.16 | 6,930 | 1.72* | 22.9* | (6.8-43.3) |
Non-Hodgkin’s lymphoma | 448 | 348.23 | 26,008 | 1.29* | 38.4* | (22.8-55.1) | 229 | 185.26 | 22,997 | 1.24* | 19.0* | (6.5-32.8) |
Multiple myeloma | 133 | 125.42 | 6,934 | 1.06 | 10.9 | (-20.3-46.4) | 73 | 66.51 | 6,946 | 1.10 | 9.3 | (-13.4-36.4) |
Leukaemia | 377 | 323.41 | 22,217 | 1.17* | 24.1* | (7.4-42.1) | 173 | 130.86 | 17,269 | 1.32* | 24.4* | (10.0-40.5) |
Acute lymphatic leukaemia | 4 | 3.21 | 3,064 | 1.25 | 2.6 | (-7.0-23.0) | 7 | 2.91 | 2,571 | 2.41 | 15.9 | (-0.4-44.8) |
Chronic lymphatic leukaemia | 276 | 219.48 | 11,261 | 1.26* | 50.2* | (22.1-80.9) | 123 | 91.97 | 9,091 | 1.34* | 34.1* | (11.3-60.3) |
Acute myeloid leukaemia | 21 | 23.63 | 2,585 | 0.89 | -10.2 | (-41.2-32.8) | 23 | 12.37 | 2,491 | 1.86* | 42.7* | (8.8-88.9) |
Chronic myeloid leukaemia | 43 | 47.36 | 3,291 | 0.91 | -13.3 | (-49.4-32.1) | 14 | 16.78 | 2,234 | 0.83 | -12.4 | (-40.9-30.0) |
Other sitesd
| 542 | 412.95 | 25,949 | 1.31* | 49.7* | (32.5-68.1) | 211 | 186.09 | 22,084 | 1.13 | 11.3 | (-1.2-25.1) |
All sites
d
|
14,555
|
10,514.87
|
689,115
|
1.38*
|
58.6*
|
(55.2-62.1)
|
6,671
|
5,040.73
|
751,845
|
1.32*
|
21.7*
|
(19.6-23.8)
|
Multivariate analyses
Males | Females | ||||||||
---|---|---|---|---|---|---|---|---|---|
(N = 160,807) | (N = 129,160) | ||||||||
Ratio of SIRs |
P
| Ratio of EARs |
P
| Ratio of SIRs |
P
| Ratio of EARs |
P
| ||
(95% CI) | (95% CI) | (95% CI) | (95% CI) | ||||||
Age at first cancer diagnosis
| ≤ 44 y | 1.98 (1.78-2.20) | <.001 | 0.63 (0.54-0.75) | <.001 | 1.27 (1.15-1.41) | <.001 | 0.54 (0.40-0.72) | <.001 |
45 y-54 y | 1.49 (1.41-1.59) | 0.93 (0.84-1.04) | 1.11 (1.03-1.20) | 0.90 (0.72-1.13) | |||||
55 y-64 y
|
1.00 (ref)
|
1.00 (ref)
|
1.00 (ref)
|
1.00 (ref)
| |||||
65 y-74 y | 0.86 (0.82-0.89) | 0.88 (0.78-1.00) | 0.93 (0.87-0.99) | 0.89 (0.69-1.14) | |||||
≥ 75 | 0.81 (0.77-0.85) | 0.67 (0.53-0.84) | 0.83 (0.77-0.89) | 0.51 (0.32-0.81) | |||||
Year of first cancer diagnosis
|
1989-1994
|
1.00 (ref)
| .271 |
1.00 (ref)
| .037 |
1.00 (ref)
| .003 |
1.00 (ref)
| <.001 |
1995-1999 | 0.97 (0.93-1.01) | 0.88 (0.79-0.97) | 1.10 (1.04-1.17) | 1.48 (1.19-1.84) | |||||
2000-2004 | 0.99 (0.95-1.03) | 0.92 (0.82-1.04) | 1.10 (1.03-1.18) | 1.44 (1.10-1.89) | |||||
Follow-up
| ≥ 2 m- < 1 y | 1.00 (0.95-1.06) | <.001 | 0.82 (0.71-0.95) | .037 | 1.05 (0.96-1.16) | .284 | 0.93 (0.62-1.33) | .006 |
≥ 1 y- < 2 y
|
1.00 (ref)
|
1.00 (ref)
|
1.00 (ref)
|
1.00 (ref)
| |||||
≥ 2 y- < 4 y | 0.99 (0.94-1.05) | 1.02 (0.90-1.17) | 1.02 (0.94-1.11) | 1.03 (0.76-1.40) | |||||
≥ 4 y- < 6 y | 0.96 (0.90-1.01) | 0.96 (0.83-1.12) | 1.00 (0.92-1.10) | 1.07 (0.76-1.49) | |||||
≥ 6 y- < 8 y | 0.95 (0.89-1.01) | 1.01 (0.85-1.20) | 1.07 (0.97-1.18) | 1.41 (1.01-1.97) | |||||
≥ 8 y- < 10 y | 0.90 (0.83-0.97) | 0.90 (0.73-1.11) | 1.00 (0.90-1.12) | 1.31 (0.89-1.94) | |||||
≥ 10 y | 0.82 (0.76-0.88) | 0.87 (0.71-1.07) | 1.10 (1.00-1.22) | 1.83 (1.28-2.62) | |||||
First cancer site
|
b
| <.001 |
b
| <.001 |
b
| <.001 |
b
| <.001 |
Estimates by site of first and second cancer
First cancer site | Second cancer site | O | E | PYR | SIRa
| EARa,b
| (95% CI) |
---|---|---|---|---|---|---|---|
Lip
| Lung, bronchus and trachea | 27 | 9.52 | 4,081 | 2.84 | 42.8 | (20.3-72.9) |
Oesophagus | 7 | 1.79 | 3.91 | 12.8 | (2.5-31.0) | ||
Head and neck
| Lung, bronchus and trachea | 663 | 76.15 | 38,731 | 8.71 | 151.5 | (138.7-165.1) |
Head and neckc
| 405 | 24.54 | 16.50 | 98.2 | (88.3-108.9) | ||
Oesophagus | 269 | 13.79 | 19.51 | 65.9 | (57.8-74.7) | ||
Larynx | 76 | 10.74 | 7.07 | 16.8 | (12.7-21.8) | ||
Colorectum | 109 | 60.09 | 1.81 | 12.6 | (7.6-18.4) | ||
Liver, primary | 62 | 17.04 | 3.64 | 11.6 | (7.9-16.1) | ||
Bladder | 53 | 24.13 | 2.20 | 7.5 | (4.0-11.7) | ||
Kidney | 35 | 17.32 | 2.02 | 4.6 | (1.8-8.1) | ||
Pancreas | 26 | 11.03 | 2.36 | 3.9 | (1.5-7.0) | ||
Stomach | 29 | 14.27 | 2.03 | 3.8 | (1.3-7.1) | ||
Oesophagus
| Head and neck | 92 | 6.29 | 7,367 | 14.63 | 116.3 | (92.1-144.6) |
Lung, bronchus and trachea | 71 | 16.70 | 4.25 | 73.7 | (52.6-98.9) | ||
Larynx | 16 | 2.25 | 7.11 | 18.7 | (9.4-32.2) | ||
Colorectum | 25 | 14.51 | 1.72 | 14.2 | (2.3-30.4) | ||
Stomach | 10 | 3.72 | 2.69 | 8.5 | (1.5-19.9) | ||
Bladder | 12 | 5.96 | 2.01 | 8.2 | (0.3-20.4) | ||
Colorectum
| Colorectumc
| 174 | 119.63 | 97,268 | 1.45 | 5.6 | (3.0-8.5) |
Lung, bronchus and trachea | 279 | 240.30 | 1.16 | 4.0 | (0.7-7.5) | ||
Bladder | 136 | 104.92 | 1.30 | 3.2 | (0.9-5.8) | ||
Larynx
| Lung, bronchus and trachea | 310 | 44.71 | 19,900 | 6.93 | 133.3 | (116.5-151.7) |
Head and neck | 138 | 15.78 | 8.75 | 61.4 | (50.3-74.0) | ||
Oesophagus | 64 | 7.59 | 8.43 | 28.3 | (21.0-37.3) | ||
Bladder | 46 | 16.25 | 2.83 | 15.0 | (8.8-22.7) | ||
Colorectum | 62 | 39.40 | 1.57 | 11.4 | (4.1-20.1) | ||
Liver, primary | 22 | 10.72 | 2.05 | 5.7 | (1.5-11.4) | ||
Stomach | 19 | 9.27 | 2.05 | 4.9 | (1.1-10.3) | ||
Pancreas | 14 | 6.96 | 2.01 | 3.5 | (0.3-8.3) | ||
Lung, bronchus and trachea
| Head and neck | 127 | 31.83 | 41,162 | 3.99 | 23.1 | (18.0-29.0) |
Bladder | 105 | 34.29 | 3.06 | 17.2 | (12.5-22.5) | ||
Oesophagus | 55 | 15.65 | 3.51 | 9.6 | (6.3-13.6) | ||
Colorectum | 121 | 84.25 | 1.44 | 8.9 | (3.9-14.7) | ||
Larynx | 45 | 12.08 | 3.73 | 8.0 | (5.0-11.7) | ||
Kidney | 45 | 21.47 | 2.10 | 5.7 | (2.8-9.4) | ||
Leukaemia | 30 | 16.07 | 1.87 | 3.4 | (1.0-6.5) | ||
Melanoma of skin
| Leukaemia | 19 | 6.22 | 20,881 | 3.06 | 6.1 | (2.5-11.2) |
Prostate
| Colorectum | 830 | 692.73 | 230,582 | 1.20 | 6.0 | (3.5-8.5) |
Bladder | 406 | 291.02 | 1.40 | 5.0 | (3.3-6.8) | ||
Testis
| Kidney | 10 | 2.38 | 19,448 | 4.20 | 3.9 | (1.2-8.2) |
Bladder
| Lung, bronchus and trachea | 295 | 94.45 | 38,002 | 3.12 | 52.8 | (44.2-62.2) |
Prostate | 398 | 257.66 | 1.54 | 36.9 | (26.9-47.7) | ||
Head and neck | 55 | 27.02 | 2.04 | 7.4 | (3.8-11.7) | ||
Larynx | 28 | 10.96 | 2.55 | 4.5 | (2.0-7.8) | ||
Stomach | 38 | 23.71 | 1.60 | 3.8 | (0.8-7.5) | ||
Kidney
| Prostate | 269 | 162.00 | 28,385 | 1.66 | 37.7 | (26.7-49.7) |
Bladder | 39 | 24.55 | 1.59 | 5.1 | (1.1-10.1) | ||
Thyroid gland
| Prostate | 34 | 20.08 | 7,369 | 1.69 | 18.9 | (4.7-37.2) |
Leukaemia | 5 | 1.50 | 3.33 | 4.7 | (0.1-13.8) | ||
Hodgkin's disease
| Lung, bronchus and trachea | 23 | 5.72 | 8,338 | 4.02 | 20.7 | (10.6-34.5) |
Non-Hodgkin’s lymphoma | 6 | 1.33 | 4.50 | 5.6 | (1.0-14.1) | ||
Oesophagus | 4 | 0.93 | 4.29 | 3.7 | (0.2-11.2) | ||
Non-Hodgkin’s lymphoma
| Lung, bronchus and trachea | 76 | 46.84 | 26,008 | 1.62 | 11.2 | (5.0-18.6) |
Leukaemia | 21 | 8.50 | 2.47 | 4.8 | (1.7-9.1) | ||
Bladder | 30 | 17.70 | 1.70 | 4.7 | (1.0-9.7) | ||
Stomach | 18 | 10.21 | 1.76 | 3.0 | (0.2-7.0) | ||
Chronic lymphatic leukaemia
| Lung, bronchus and trachea | 56 | 27.69 | 11,261 | 2.02 | 25.1 | (13.0-40.0) |
Colorectum | 41 | 27.78 | 1.48 | 11.7 | (1.5-24.7) | ||
Hodgkin’s disease | 4 | 0.39 | 10.26 | 3.2 | (0.6-8.7) |
First cancer site | Second cancer site | O | E | PYR | SIRa
| EARa,b
| (95% CI) |
---|---|---|---|---|---|---|---|
Head and neck
| Head and neckc
| 57 | 0.61 | 7,781 | 93.83 | 72.5 | (54.7-94.1) |
Lung, bronchus and trachea | 51 | 2.71 | 18.81 | 62.1 | (45.3-82.7) | ||
Oesophagus | 20 | 0.41 | 49.33 | 25.2 | (15.2-39.2) | ||
Liver, primary | 5 | 0.69 | 7.25 | 5.5 | (1.2-14.1) | ||
Oesophagus
| Head and neck | 10 | 0.14 | 1,244 | 71.04 | 79.3 | (37.4-146.7) |
Colorectum
| Breast | 297 | 246.36 | 87,123 | 1.21 | 5.8 | (2.0-9.9) |
Colorectumc
| 98 | 67.48 | 1.45 | 3.5 | (1.4-6.0) | ||
Corpus uteri | 66 | 41.93 | 1.57 | 2.8 | (1.0-4.8) | ||
Liver, primary
| Lung, bronchus and trachea | 5 | 0.61 | 1,709 | 8.13 | 25.7 | (5.8-64.7) |
Non-Hodgkin’s lymphoma | 3 | 0.53 | 5.62 | 14.4 | (0.4-48.2) | ||
Soft tissue | 2 | 0.06 | 32.96 | 11.3 | (1.0-41.9) | ||
Larynx
| Lung, bronchus and trachea | 19 | 0.74 | 1,995 | 25.76 | 91.5 | (53.6-145.0) |
Head and neck | 10 | 0.22 | 45.47 | 49.0 | (22.9-91.1) | ||
Oesophagus | 3 | 0.11 | 26.70 | 14.5 | (2.5-43.4) | ||
Bladder | 3 | 0.28 | 10.73 | 13.6 | (1.6-42.5) | ||
Lung, bronchus and trachea
| Head and neck | 10 | 0.99 | 9,446 | 10.09 | 9.5 | (4.0-18.4) |
Bladder | 6 | 1.18 | 5.11 | 5.1 | (1.1-12.6) | ||
Oesophagus | 3 | 0.47 | 6.41 | 2.7 | (0.1-8.8) | ||
Soft tissue
| Ovary and uterine adnexa | 4 | 0.86 | 3,951 | 4.68 | 8.0 | (0.6-23.8) |
Melanoma of skin
| Breast | 98 | 75.05 | 32,127 | 1.31 | 7.1 | (1.4-13.8) |
Kidney | 15 | 5.32 | 2.82 | 3.0 | (1.0-6.0) | ||
Breast
| Corpus uteri | 358 | 147.83 | 351,434 | 2.42 | 6.0 | (5.0-7.1) |
Cervix uteri
| Lung, bronchus and trachea | 34 | 7.66 | 28,122 | 4.44 | 9.4 | (5.6-14.2) |
Colorectum | 40 | 22.60 | 1.77 | 6.2 | (2.1-11.3) | ||
Vagina and vulva | 10 | 1.28 | 7.82 | 3.1 | (1.2-6.1) | ||
Leukaemia | 12 | 4.17 | 2.88 | 2.8 | (0.7-6.0) | ||
Bladder | 10 | 2.45 | 4.08 | 2.7 | (0.8-5.7) | ||
Corpus uteri
| Breast | 174 | 120.03 | 41,147 | 1.45 | 13.1 | (7.1-19.9) |
Colorectum | 106 | 60.33 | 1.76 | 11.1 | (6.4-16.5) | ||
Lung, bronchus and trachea | 34 | 17.06 | 1.99 | 4.1 | (1.6-7.4) | ||
Vagina and vulva
| Cervix uteri | 6 | 0.68 | 4,219 | 8.87 | 12.6 | (3.6-29.4) |
Bladder | 4 | 0.88 | 4.53 | 7.4 | (0.5-22.2) | ||
Head and neck | 3 | 0.47 | 6.37 | 6.0 | (0.3-19.7) | ||
Kidney
| Breast | 62 | 46.58 | 17,327 | 1.33 | 8.9 | (0.6-19.0) |
Lung, bronchus and trachea | 16 | 6.61 | 2.42 | 5.4 | (1.5-11.2) | ||
Leukaemia | 11 | 4.07 | 2.70 | 4.0 | (0.8-9.0) | ||
Thyroid gland | 8 | 2.70 | 2.96 | 3.1 | (0.4-7.5) | ||
Thyroid gland
| Leukaemia | 13 | 3.95 | 31,397 | 3.29 | 2.9 | (0.9-5.8) |
Hodgkin’s disease
| Leukaemia | 5 | 0.50 | 6,930 | 10.05 | 6.5 | (1.6-16.1) |
Non-Hodgkin’s lymphoma | 5 | 0.73 | 6.89 | 6.2 | (1.3-15.8) | ||
Lung, bronchus and trachea | 4 | 0.97 | 4.14 | 4.4 | (0.2-13.4) | ||
Non-Hodgkin’s lymphoma
| Stomach | 12 | 5.02 | 22,997 | 2.39 | 3.0 | (0.5-6.9) |
Kidney | 12 | 4.99 | 2.41 | 3.0 | (0.5-6.9) | ||
Chronic lymphatic leukaemia
| Breast | 41 | 26.30 | 9,091 | 1.56 | 16.2 | (3.4-32.3) |
Acute myeloid leukaemia
| Ovary and uterine adnexa | 3 | 0.48 | 2,491 | 6.26 | 10.1 | (0.5-33.3) |
Discussion
Main findings of this study
Patterns of first and second primary cancers
High tobacco and/or alcohol consumption
Hormonal and nutritional factors
Exposure to virus and immunosuppression
Genetic predisposition
Increased site-specific medical surveillance
Late adverse effects of first cancer treatments
Interactions among these factors
Methodological considerations
-
on the one hand, a decrease of the number of cases that may have been observed in subsequent follow-up periods or,
-
on the other hand, to keeping patients who present a particularly high carcinogenic exposition and thus carry the highest risk of new malignancy.